Sandeep Soni, MD
Pediatric Hematology-Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Soni’s office at (650) 497-8000 to ask if they take your plan before you enroll.
California Medical Board record
Licence C146913 · Current
Licensed to practise in California · since 2017 · expires 2028-08-31 · University of Delhi, Maulana Azad Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Pediatric Hematology-Oncology
Money from drug and device companies
$18 in 2025
| 2025 | 1 | 1 | None | $18 |
| 2023 | 2 | 2 | None | $50 |
| 2019 | 1 | 1 | $2,140 | $2,140 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Shionogi | Fetroja | $18 | 1 payment
|
See the published payment
| Shionogi | Meals · 2025-08-05 | Fetroja | $18 |
See earlier years (2023, 2019)
2023: $50
| Gilead Sciences | None | $31 | 1 payment
|
| Shionogi | Fetroja | $19 | 1 payment
|
2019: $2,140
| Vertex Pharmaceuticals | None | $2,140 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| VERTEX PHARMACEUTICALS INCORPORATED · A Safety and Efficacy Study Evaluating Ctx001 in Subjects With Severe Sickle Cell Disease · 2021 | Their institution | $1,068,587 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Safety and Efficacy Study Evaluating Ctx001 in Subjects With Severe Sickle Cell Disease · 2022 | Their institution | $230,659 |
| Vertex Pharmaceuticals Incorporated · A Phase 1/2 Study of the Safety and Efficacy of A Single Dose of Autologous Crispr-Cas9 Modified Cd34+ Human Hematopoietic Stem and Progenitor Cells (Hhspcs) in Subjects With Transfusion-Dependent Beta-Thalassemia · 2020 | Their institution | $64,969 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Safety and Efficacy Study Evaluating Ctx001 in Subjects With Severe Sickle Cell Disease · 2019 | Their institution | $33,554 |
| Vertex Pharmaceuticals Incorporated · A Safety and Efficacy Study Evaluating Ctx001 in Subjects With Severe Sickle Cell Disease · 2020 | Their institution | $25,450 |
| Vertex Pharmaceuticals Incorporated · A Phase 1/2 Study of the Safety and Efficacy of A Single Dose of Autologous Crispr-Cas9 Modified Cd34+ Human Hematopoietic Stem and Progenitor Cells (Hhspcs) in Subjects With Transfusion-Dependent Beta-Thalassemia · 2021 | Their institution | $126 |
Professional record
- NPI
- 1104807718
- Licence
- CA C146913, OH 35088674California C146913: Current · expires 2028-08-31
More record details
- Sole proprietor
- No
- Medicaid ID
- OH 2694633
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2005-11-10
- NPI last updated
- 2017-02-10
This is when the NPI record was last certified, not a medical board exam.